Literature DB >> 11130891

Neutralization of Toscana virus is partially mediated by antibodies to the nucleocapsid protein.

M G Cusi1, P E Valensin, M Donati, M Valassina.   

Abstract

The envelope glycoproteins G1/G2 of Toscana virus (TOSV) seem to have the most important protective role in stimulating antibodies against the disease in humans, as well as antibodies against the Nucleoprotein (N), a partial neutralizing activity. Mice immunized with TOSV recombinant Nucleoprotein developed a strong humoral response to the TOSV that revealed the presence of neutralizing antibody than in vitro assay. The neutralizing antibody titre of mice immunized with the whole TOSV was analyzed before and after absorption of the sera with the recombinant N protein. A decrease of the neutralizing activity was observed in the treated sera. Similar results were obtained absorbing human anti-TOSV positive sera with the recombinant N protein. This study was designed to identify the nature of antibodies produced against the N protein of TOSV in mice and to establish correlation with antibodies produced in humans by natural infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11130891

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.

Authors:  Steven A Rubin; Malen A Link; Christian J Sauder; Cheryl Zhang; Laurie Ngo; Bert K Rima; W Paul Duprex
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Performance of various commercial assays for the detection of Toscana virus antibodies.

Authors:  Koray Ergünay; Nadine Litzba; Modou Moustapha Lo; Sibel Aydoğan; Mehmet B Saygan; Dürdal Us; Manfred Weidmann; Matthias Niedrig
Journal:  Vector Borne Zoonotic Dis       Date:  2011-03-11       Impact factor: 2.133

Review 3.  A Mediterranean arbovirus: the Toscana virus.

Authors:  Marcello Valassina; Maria Grazia Cusi; Pier Egisto Valensin
Journal:  J Neurovirol       Date:  2003-12       Impact factor: 2.643

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.